Prospective study of the efficacy of intravesical chemotherapy with THP against subsequent bladder cancer after nephrouretectomy (NUx) for upper urinary tract carcinoma (UUTC).

Prospective study of the efficacy of intravesical chemotherapy with THP against subsequent bladder cancer after nephrouretectomy (NUx) for upper urinary tract carcinoma (UUTC). - Prospective study of the efficacy of intravesical chemotherapy against bladder recurrence after NUx for UUTC.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005767

Enrollment

100

Registered

2011-07-01

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma of upper urinary tract

Interventions

Intravesical infusion of pirarubicin (30mg/40ml) immediately after nephroureterectomy. No intravesical infusion of pirarubicin immediately after nephroureterectomy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients 20 or older Performance status scale 0~1 Patients diagnosed as having upper urinary tract carcinoma by CT, urine cytology or pyeloureteroscopy. Tumor-stage is diagnosed by imaging test as lower than T3 and N0M0 Patients expected survival is 3 months or longer Patients must have functioning organs Liver :AST and ALT should be within 3 times the range of the limit set by their assigned facility heart :no significant abnormal electrocardiogram readings(irregular heartbeat, angina, heart failure, heart infarction) Kidney :no kidney failure Patients must give written informed consent

Exclusion criteria

Exclusion criteria: Prior bladder cancer Carcinoma in situ, or treatment history for carcinoma in situ Severe diabetes Uncontrollable complications Severe mental diseases Active multiple cancers Anthracycline sensitivity Patients diagnosed as inappropriate

Design outcomes

Primary

Measure	Time frame
Bladder recurrence free rate.	—

Secondary

Measure	Time frame
Disease-specific survival. Safety.	—

Countries

Japan

Contacts

Public ContactYasuyuki Kobayashi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science. Department of Urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026